Table 3 Multivariable analysis of development of NFV resistance at failure
Variable | Coefficient (β) | SE | P Value | Odds Ratio | 95% CI |
|---|---|---|---|---|---|
Intercept | 1.68 | 1.27 | Â | Â | Â |
log | -0.51 | 0.56 | .36 | 0.60 | 0.20 - 1.79 |
| -0.61 | 0.26 | .02 | 0.54 | 0.32 - 0.91 |
GSS Other , per unit higher | -0.72 | 0.17 | < .001 | 0.49 | 0.35 - 0.67 |
ΔT, per month more | < 0.001 | < 0.001 | .14 | 1.00 | 0.99 - 1.01 |
Sub, as B | 0.55 | 0.38 | .15 | 1.73 | 0.82 - 3.64 |
Variable | Coefficient ( β ) | SE | P Value | Odds Ratio | 95% CI |
Intercept | 3.31 | 1.44 | Â | Â | Â |
log | -0.67 | 0.56 | .24 | 0.51 | 0.17 - 1.56 |
| -0.02 | 0.005 | .008 | 0.98 | 0.97 - 0.99 |
GSS Other , per unit higher | -0.74 | 0.17 | < .001 | 0.47 | 0.34 - 0.66 |
ΔT, per month more | < 0.001 | < 0.001 | .14 | 1.00 | 0.99 - 1.01 |
Sub, as B | 0.41 | 0.38 | .29 | 1.51 | 0.70 - 3.23 |
, per unit higher
, per additional mutation
, per 10 generations more- A multivariable logistic regression model is shown for development of nelfinavir (NFV) resistance at treatment failure starting from the baseline genotype based on the expected number of mutations to NFV resistance (
) in the upper table and based on the expected number of generations to NFV resistance (
) in the lower table. Analyses are corrected for duration between baseline and follow-up sequence (ΔT), fitness under NFV treatment (log 
), the activity score of the combination excluding NFV (GSS
Other
) and the subtype distribution (Sub).